Literature DB >> 1688625

Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.

M Roivainen1, B Montagnon, H Chalumeau, M Murray, E Wimmer, T Hovi.   

Abstract

Previous studies showed that the distribution of antigenic site specificity of neutralizing antibodies to type 3 poliovirus obtained with the inactivated poliovirus vaccine can be deficient as compared with that obtained following poliovirus infection. This observation was shown by the relatively low capacity of sera from inactivated-poliovirus-vaccine-immunized persons to neutralize poliovirus cleaved at antigenic site 1. We investigated possibilities for improving the situation in a mouse model. Balb/c mice were immunized with intact or trypsin-cleaved type 3 poliovirus (Saukett strain). Sera from mice immunized with the intact virus readily neutralized the intact virus but neutralized the cleaved virus only rarely. In contrast, cleaved-virus-immunized mice produced antibodies that were able to neutralize the cleaved virus as well as the intact one. Mice immunized with a 100-fold-higher dose of the intact virus produced significant levels of antibodies to the cleaved virus, too. Somewhat surprisingly, mice immunized with high doses of the cleaved virus produced antibodies specific for the intact loop between beta sheets B and C of VP1 (virion protein 1), which should be cleaved in the immunogen. This was shown by a higher titer of antibodies to intact Saukett virus than to the corresponding cleaved virus, as well as to a type 1/type 3 hybrid poliovirus in which only the BC loop amino acids were derived from type 3 poliovirus. The cleavage-induced enhanced availability of antigenic determinants residing outside the BC loop was also shown by increased neutralization titers of monoclonal antibodies specific for some of these other determinants. These results indicate that by using a trypsin-cleaved type 3 poliovirus as a parenteral immunogen, it is possible to change the distribution of antigenic site specificities of neutralizing antibodies to resemble that following poliovirus infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688625      PMCID: PMC249144     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  9 in total

1.  Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

3.  Partial RNA sequencing of eight supposed derivatives of type 3 poliovirus/USA/Saukett/50 reveals remarkable differences between three apparent substrains.

Authors:  L Kinnunen; T Hovi
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

4.  Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles.

Authors:  C E Fricks; J P Icenogle; J M Hogle
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

5.  Detection of poliovirus antigen by enzyme immunoassay.

Authors:  P Ukkonen; A Huovilainen; T Hovi
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

6.  Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.

Authors:  J P Icenogle; P D Minor; M Ferguson; J M Hogle
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

7.  Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.

Authors:  M Roivainen; T Hovi
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Radiometric cytolysis inhibition assay, a new rapid test for neutralizing antibodies to intact and trypsin-cleaved poliovirus.

Authors:  T Hovi; M Roivainen
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

9.  Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys.

Authors:  M G Murray; R J Kuhn; M Arita; N Kawamura; A Nomoto; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

  9 in total
  5 in total

1.  Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.

Authors:  M M Herremans; J H Reimerink; A Ras; H G Van Der Avoort; T G Kimman; A M Van Loon; M A Conyn-Van Spaendonck; M P Koopmans
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

2.  Selective cleavage by trypsin of the capsid protein VP1 of type 3 poliovirus results in improved sorting of cell bound virions.

Authors:  L Piirainen; A Airaksinen; T Hovi; M Roivainen
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Deficiency of immunity to poliovirus type 3: a lurking danger?

Authors:  Claudia Reinheimer; Imke Friedrichs; Holger F Rabenau; Hans W Doerr
Journal:  BMC Infect Dis       Date:  2012-01-26       Impact factor: 3.090

4.  Epidemiological serosurvey of poliovirus in Guangdong, China: A cross-sectional study.

Authors:  Qiu Tan; Qi Zhu; Huanying Zheng; Bing Zhang; Chenggang Wu; Xue Guo; Hui Li; Leng Liu; Yu Liu; Shannon Rutherford; Huizhen Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-07-30       Impact factor: 3.452

5.  Assessment of seroprevalence against poliovirus among Italian adolescents and adults.

Authors:  Silvia Lupi; Armando Stefanati; Tatjana Baldovin; Alberto Roman; Vincenzo Baldo; Giovanni Gabutti
Journal:  Hum Vaccin Immunother       Date:  2018-12-20       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.